

University of Groningen

Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?

Ismail, R K; van Breeschoten, J; Wouters, M W J M; van Dartel, M; van der Flier, S; Reyners, A K L; de Graeff, P; Pasmooij, A M G; de Boer, A; Broekman, K E

Published in:
The Breast

DOI:
[10.1016/j.breast.2022.01.011](https://doi.org/10.1016/j.breast.2022.01.011)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Ismail, R. K., van Breeschoten, J., Wouters, M. W. J. M., van Dartel, M., van der Flier, S., Reyners, A. K. L., de Graeff, P., Pasmooij, A. M. G., de Boer, A., Broekman, K. E., & Hilarius, D. L. (2022). Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions? *The Breast*, 62, 180-180. <https://doi.org/10.1016/j.breast.2022.01.011>

Copyright


Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?

Dear Editor,

We want to thank dr. Regan for reading and commenting on our manuscript “Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer”. We would like to mention that this study was hypothesis-generating. We were aware of the limitations of this type of observational data used in this study, as described in the manuscript. To limit immortal time bias, we described an additional survival analysis in the manuscript, excluding the patients that stopped treatment (presumably due to early progression) within the first three months of treatment. Furthermore, most dose reductions occurred early during treatment, and from a clinical point of view a substantial part of the patients stopping treatment because of AEs, will have experienced a dose reduction before stopping treatment.

However, we considered the suggestion for the landmark analysis and performed this in-depth analysis on the dataset. The landmark analysis did not lead to different conclusions for this study. The overall survival between patients with a dose reduction was significantly higher compared to patients without a dose reduction ($p = 0.019$). We agree with dr. Regan that this analysis is the most suitable to limit immortal time bias, and we will use this in comparable future research.

R.K. Ismail^{a,b,*}, J. van Breeschoten^{a,c}, M.W.J.M. Wouters^{a,d,e}, M. van Dartel^f, S. van der Flier^g, A.K.L. Reyners^h, P. de Graeff^f, A.M. G. Pasmooij^f, A. de Boer^{b,f}, K.E. Broekman^{f,h}, D.L. Hilarius^j
^a Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, the Netherlands

^b Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands

^c Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan, 1118, Amsterdam, 1081HZ, the Netherlands

^d Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands

^e Department of Biomedical Data Sciences, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333ZA, the Netherlands

^f Medicines Evaluation Board, Graadt van Roggenweg 500, Utrecht, 3531AH, the Netherlands

^g Coöperatie VGZ U.A, Nieuwe Stationsstraat 12, Arnhem, 6811KS, the Netherlands

^h Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713, GZ, the Netherlands

ⁱ University of Groningen, University Medical Center Groningen, University Center for Geriatric Medicine, Hanzeplein 1, Groningen, 9700, RB, the Netherlands

^j Department of Pharmacy, Rode Kruis Ziekenhuis, Vondellaan 13, Beverwijk, 1942LE, the Netherlands

* Corresponding author. Rijnsburgerweg 10, 2333AA, Leiden, the Netherlands.

E-mail address: r.ismail@dica.nl (R.K. Ismail).

DOIs of original article: <https://doi.org/10.1016/j.breast.2021.11.013>, <https://doi.org/10.1016/j.breast.2021.12.020>.

<https://doi.org/10.1016/j.breast.2022.01.011>

Available online 29 January 2022

0960-9776/© 2022 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).